Fig. 3: Serum reactivity to different IBV antigens. | Nature Communications

Fig. 3: Serum reactivity to different IBV antigens.

From: Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses

Fig. 3

Mice were vaccinated with a prime only or prime-boost vaccination regimen (28 days apart) I.D. with 5 μg of monovalent mRNA-LNPs or with 5 μg/antigen or 1 μg/antigen of the pentavalent mRNA-LNP formulation. Control animals received 5 μg of luciferase mRNA-LNP. Sera were collected on day 28 post prime and post boost and binding of antibodies to influenza antigens was measured by ELISA. Binding of sera against B/Phuket/307/2013 HA (n = 25 prime-only samples, n = 10 prime-boost samples). (a) B/Colorado/06/2017 HA (n = 25 prime-only samples, n = 10 prime-boost samples). (b) B/Phuket/307/2013 NA (n = 10) (c) B/Colorado/06/2017 NA (n = 25 prime-only samples, n = 10 prime-boost samples) (d) B/Colorado/06/2017 NP (n = 10) (e) and B/Colorado/06/2017 M2 (n = 5) (f). Each symbol represents one animal. AUCs with a cutoff value of the average background plus three SDs are shown. Bars represent the mean of each group. The dotted lines indicate the limit of detection. Source data are provided as a source data file.

Back to article page